Migraines can significantly reduce the quality of life of those affected. Early treatment is therefore advisable if the diagnosis is confirmed. Migraine therapy can be divided into three groups: Acute therapy, prophylaxis, non-drug measures. Monoclonal antibodies against CGRP and the CGRP receptor are now well established for long-term drug prophylaxis. The new up-and-coming generation of migraine drugs includes Ditane and Gepante.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people
Benefit of the high-dose influenza vaccine
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Artificial intelligence